Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM8MJ3F)

Drug Name
PB1046 Drug Info
Synonyms Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Phase 2 [1]
Pulmonary arterial hypertension BB01.0 Phase 2 [2]
Cardiomyopathy BC43 Phase 1 [3]
Duchenne dystrophy 8C70 Phase 1 [1]
Hypertension BA00-BA04 Phase 1 [4]
Cross-matching ID
TTD Drug ID
DM8MJ3F

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Helodermin-preferring VIP receptor (VIPR2) TT4O5P0 VIPR2_HUMAN Agonist [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Helodermin-preferring VIP receptor (VIPR2) DTT VIPR2 1.632 3.888 3.293 3.087
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Heart failure
ICD Disease Classification BD10-BD13
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Helodermin-preferring VIP receptor (VIPR2) DTT VIPR2 1.54E-01 -0.08 -0.4
Helodermin-preferring VIP receptor (VIPR2) DTT VIPR2 6.31E-01 6.73E-03 0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03795428) Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of PhaseBio.
5 Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.